Literature DB >> 14607876

Anti-HBs cellular immune response in kidney recipients before and 4 months after transplantation.

Patricia Aguilar1, Edith Renoult, Loraine Jarrosson, Marie Nathalie Kolopp-Sarda, Christine Prin Mathieu, Gilbert C Faure, Michele Kessler, Marie C Bene, Chantal Kohler, Anne Kennel De March.   

Abstract

Patients with renal failure represent a population at risk for hepatitis B, since only 50 to 60% of them develop protective humoral responses after vaccination. As this could be due to an altered regulation of cellular immune responses, the objectives of the present study were to evaluate the proliferative abilities of lymphocytes from patients with chronic renal failure after stimulation in vitro with a mitogen (pokeweed mitogen [PWM]) or HBsAg. In order to differentiate between the immunodeficiency associated with renal failure and that due to immunosuppression posttransplantation, the same subjects were tested before and 4 months after kidney transplantation. The lymphoproliferation assay used was performed by flow cytometry, which is based on sequential analysis of the cell cycle and which allows analysis of cytokine production. Serologically, the group of 36 patients tested comprised 22% nonresponders, 30% poor responders, and 48% responders. Lymphocyte growth was observed for all patients after stimulation with PWM, indicating that these cells had the capacity to proliferate in vitro. The level of lymphoproliferation in response to PWM was significantly reduced after transplantation, yet both before and after transplantation, all serologic nonresponders developed cellular responses to at least two vaccines. No correlation between humoral and cellular responses was shown. Proliferating cells were lymphocytes, which mostly secreted interleukin 4 (IL-4) and IL-10 for the three serologic groups. This study suggests that even when repeated vaccination fails to induce significant antibody levels in patients with renal failure, specific HBs cellular responses develop, and these may prove to be efficient in protecting these patients against hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607876      PMCID: PMC262442          DOI: 10.1128/cdli.10.6.1117-1122.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  20 in total

1.  Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines.

Authors:  I Desombere; Y Gijbels; A Verwulgen; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Factors influencing response to hepatitis B virus vaccination in hemodialysis patients.

Authors:  S Sezer; F N Ozdemir; G Güz; Z Arat; T Colak; S Sengul; M Turan; A Haberal; R Erdal
Journal:  Transplant Proc       Date:  2000-05       Impact factor: 1.066

3.  Normal HBsAg presentation and T-cell defect in the immune response of nonresponders.

Authors:  M Salazar; H Deulofeut; C Granja; R Deulofeut; D E Yunis; D Marcus-Bagley; Z Awdeh; C A Alper; E J Yunis
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

4.  Detection of beryllium sensitivity using a flow cytometric lymphocyte proliferation test: the Immuno-Be-LPT.

Authors:  G M Farris; L S Newman; E L Frome; Y Shou; E Barker; R C Habbersett; L Maier; H N Smith; B L Marrone
Journal:  Toxicology       Date:  2000-02-21       Impact factor: 4.221

Review 5.  [Viral hepatitis in hemodialysis and renal transplantation patients].

Authors:  S Pol; C Legendre
Journal:  Nephrologie       Date:  1994

6.  Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients.

Authors:  P Jungers; P Chauveau; A M Couroucé; P Devillier; J L Excler; F Bailleux; P Saliou
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

7.  [Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity].

Authors:  P Jungers; P Chauveau; A M Couroucé; A Abbassi; P Devillier; F N Marie; F Bailleux; J L Excler; J E Cerisier; P Saliou
Journal:  Presse Med       Date:  1994-02-12       Impact factor: 1.228

8.  Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.

Authors:  K el-Reshaid; S al-Mufti; K V Johny; T N Sugathan
Journal:  Vaccine       Date:  1994       Impact factor: 3.641

9.  T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway.

Authors:  M Girndt; H Köhler; E Schiedhelm-Weick; K H Meyer zum Büschenfelde; B Fleischer
Journal:  Kidney Int       Date:  1993-08       Impact factor: 10.612

10.  Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition.

Authors:  J Stachowski; M Pollok; C Barth; J Maciejewski; C A Baldamus
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.